The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global high content screening market reached a value of US$ 612 Million in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations. It is an integration of modern cell biology, flow cytometry and robotic handling that involves fluorescence imaging for analyzing various biochemical and physical characteristics of the sample cells. This aids in drug discovery, complex multivariate drug profiling and toxicity studies, while utilizing robots, detectors and software to monitor the entire process.
The increasing prevalence of neurodegenerative diseases across the globe, such as Alzheimer’s and Parkinson’s, is one of the key factors driving the market growth. The rising need for cost-effective drug discovery systems in the pharmaceutical industry is also providing a boost to the market growth. In comparison to the traditionally used methods, HCS solutions prove to be inexpensive and resource- and time-efficient for analyzing the potential toxicity of chemicals and complex substances. Advancements in informatics solutions and imaging instruments are acting as another growth-inducing factor. HCS equipment manufacturers are producing innovative equipment that is integrated with software platforms and artificial intelligence (AI) systems to enhance the visualization capabilities of the devices. In line with this, the development of automated systems for analyzing cell separation and scalability has further enhanced the adoption of HCS technology. Other factors, including the rising geriatric population and increasing investments in the research and development (R&D) of advanced screening systems, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global high content screening market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and end-user.
Breakup by Product:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific, Yokogawa Electric Corporation, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific and Yokogawa Electric Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at